Eurocine Vaccines publishes its interim report July 2021 – March 2022
2022-01-01 – 2022-03-31 (third quarter)
- Earnings after tax for the quarter amounted to -5.6 Mkr (-4.6 Mkr)
- Revenue for the quarter was Tkr 0 (Tkr 75)
- Earnings per share for the quarter amounted to -0.397 kr (-0.582 kr)
2021-07-01 – 2022-03-31 (nine month period)
- The result after tax for the period amounts to -15.0 Mkr (-12.2 Mkr)
- Revenue for the period amounted to 0 Tkr (457 Tkr)
- Earnings per share for the period amount to -1,053 kr (-1,544 kr)
Highlights of the period
In
As part of the agreement to secure the redemption of the warrants in February, Flerie Invest entered into a blocking agreement for 100% of its stake, corresponding to 13% of the total share capital and votes of the company.
In
Highlights after period
Vaccines Announced Date of Conversion of Interim Shares
In
CEO
Our third quarter is now complete and, in addition to our continued efforts to initiate the clinical phase of our chlamydia vaccine candidate, we have also been focused on further developing our portfolio of vaccine candidates. The start of 2022 has meant intensive work, evaluating and negotiating additional vaccine candidates that I look forward to sharing with the market. The expansion of our portfolio of innovative vaccine candidates is a strong lever of value for the company, given the
Internationally as in
During the quarter, we successfully completed the exercise of the warrant, and I would like to thank all those who chose to exercise their TO 4. Significant work is currently underway to ensure the quality of the various stages of the process of manufacturing for clinical trial. The capital will finance, among other things, this work. In total, approximately 84.5% of the TO 4 were subscribed and, in combination with the support of our main shareholder, Flerie Invest, we were able to reach 100% of the issue volume. This will fund near-future goals such as scale-up and manufacturing of the investigational product and the start of the toxicology study before the planned start of the clinical trial in the first half of 2023.
Building a vaccine portfolio takes time and requires a broad combination of skills and experience in vaccine development, vaccine markets, legal and business development, skills that the management team of
In addition to identifying, evaluating and negotiating other vaccine candidates, where we have recently focused on evaluation and negotiation, we are also working long-term to prepare vaccine companies who are our potential future partners. for the chlamydia vaccine candidate. Even though the vaccine market is relatively concentrated on a limited number of large global players, I am very pleased with the interest I am seeing, both in partnership conferences and in direct contacts within our large network.
As we approach the end of the fiscal year, I look back on a year of development in which we completed a number of important activities that resulted in a solid foundation for planning our next clinical trial with the candidate vaccine against chlamydia.
Finally, I would like to thank all the shareholders of
Please follow us on upcoming activities, which will appear in our Scheduleand discover our latest presentation, Aktiedagen Stockholm on March 14.
Hans Arwidsson – VD,
Hans Arwidsson, Ph.D., MBA
CEO of
[email protected]
+46 70 634 0171
Through its portfolio strategy, innovative vaccine candidates have the opportunity to reach the market faster, while investors are offered risk diversification with significant future leverage. These candidates are then licensed to partners for commercialization.
The company has its own technology platform, Endocine(TM), which has been tested in four extensive clinical studies with over 400 subjects.
Listed at
https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-publishes-interim-report-for-july-2021—march-2022,c3571105
https://mb.cision.com/Main/11552/3571105/1582380.pdf
https://mb.cision.com/Public/11552/3571105/9681ff23e6daa0af.pdf
(c) Decision 2022. All rights reserved., sources
Comments are closed.